Dimitrios Daoussis

List of Publications by Year
in descending order

79 papers	2,263 citations	279798 23 h-index	233421 45 g-index
80 all docs	80 docs citations	80 times ranked	2414 citing authors

#	Article	IF	Citations
1	Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology, 2010, 49, 271-280.	1.9	348
2	Evidence that Dkkâ€1 is dysfunctional in ankylosing spondylitis. Arthritis and Rheumatism, 2010, 62, 150-158.	6.7	223
3	A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Seminars in Arthritis and Rheumatism, 2017, 46, 625-631.	3.4	169
4	Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World Journal of Gastroenterology, 2019, 25, 2162-2176.	3.3	122
5	Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clinical and Experimental Rheumatology, 2012, 30, S17-22.	0.8	115
6	The Emerging Role of Dickkopf-1 in Bone Biology: Is It the Main Switch Controlling Bone and Joint Remodeling?. Seminars in Arthritis and Rheumatism, 2011, 41, 170-177.	3.4	86
7	Biologics in SAPHO syndrome: A systematic review. Seminars in Arthritis and Rheumatism, 2019, 48, 618-625.	3.4	74
8	Treatment of Systemic Sclerosis-Associated Calcinosis: A Case Report of Rituximab-Induced Regression of CREST-Related Calcinosis and Review of the Literature. Seminars in Arthritis and Rheumatism, 2012, 41, 822-829.	3.4	68
9	Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. Frontiers in Immunology, 0, 13, .	4.8	59
10	The Infectious Basis of ACPA-Positive Rheumatoid Arthritis. Frontiers in Microbiology, 2017, 8, 1853.	3.5	54
11	Wnt Pathway and IL-17: Novel Regulators of Joint Remodeling in Rheumatic Diseases. Looking Beyond the RANK-RANKL-OPG Axis. Seminars in Arthritis and Rheumatism, 2010, 39, 369-383.	3.4	53
12	Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature. Seminars in Arthritis and Rheumatism, 2010, 40, 127-136.	3.4	48
13	Intestinal Involvement in Systemic Sclerosis: A Clinical Review. Digestive Diseases and Sciences, 2018, 63, 834-844.	2.3	44
14	The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, 409-417.	3.4	41
15	B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence. International Journal of Rheumatology, 2011, 2011, 1-7.	1.6	35
16	B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Research and Therapy, 2012, 14, R145.	3.5	33
17	ACTH as first line treatment for acute gout in 181Âhospitalized patients. Joint Bone Spine, 2013, 80, 291-294.	1.6	33
18	Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Seminars in Arthritis and Rheumatism, 2019, 48, 1133-1141.	3.4	32

#	Article	IF	Citations
19	Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatology International, 2021, 41, 33-42.	3.0	32
20	B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Research and Therapy, 2016, 18, 118.	3.5	28
21	Primary SjÃ¶grenâ€™s Syndrome and Cardiovascular Disease. Current Vascular Pharmacology, 2020, 18, 447-454.	1.7	28
22	Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?. Current Rheumatology Reports, 2019, 21, 15.	4.7	26
23	An MRI study of immune checkpoint inhibitorâ€“induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. Rheumatology, 2020, 59, 1041-1050.	1.9	25
24	Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2009, 11, R116.	3.5	24
25	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Research and Therapy, 2018, 20, 267.	3.5	24
26	B cells tell scleroderma fibroblasts to produce collagen. Arthritis Research and Therapy, 2013, 15, 125.	3.5	23
27	A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis. Clinical Immunology, 2019, 207, 87-96.	3.2	20
28	Comorbidity burden in systemic sclerosis: beyond disease-specific complications. Rheumatology International, 2019, 39, 1507-1517.	3.0	19
29	Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 3389.	4.1	19
30	Immune checkpoint inhibitor-induced myo-fasciitis. Rheumatology, 2017, 56, 2161-2161.	1.9	18
31	Uric acid and cardiovascular risk in rheumatoid arthritis. Rheumatology, 2011, 50, 1354-1355.	1.9	17
32	ACTH as a treatment for acute crystal-induced arthritis: Update on clinical evidence and mechanisms of action. Seminars in Arthritis and Rheumatism, 2014, 43, 648-653.	3.4	17
33	Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. Journal of Bone and Mineral Research, 2016, 31, 630-639.	2.8	17
34	ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine, 2014, 81, 98-100.	1.6	16
35	The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma?. Seminars in Arthritis and Rheumatism, 2017, 46, 430-438.	3.4	16
36	Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation. Clinical Rheumatology, 2011, 30, 477-484.	2.2	15

#	Article	IF	Citations
37	Anti-TNFÎ± treatment decreases the previously increased serum Indian Hedgehog levels in patients with ankylosing spondylitis and affects the expression of functional Hedgehog pathway target genes. Seminars in Arthritis and Rheumatism, 2015, 44, 646-651.	3.4	15
38	Targeting very early systemic sclerosis: a case-based review. Rheumatology International, 2019, 39, 1961-1970.	3.0	15
39	B cells in systemic sclerosis: from pathophysiology to treatment. Clinical Rheumatology, 2021, 40, 2621-2631.	2.2	15
40	Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis. Current Medicinal Chemistry, 2015, 22, 1943-1955.	2.4	15
41	Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. Mediterranean Journal of Rheumatology, 2019, 30, 33-37.	0.8	14
42	Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. Rheumatology International, 2021, 41, 1839-1843.	3.0	13
43	Dkk1: A key molecule in joint remodelling and fibrosis. Mediterranean Journal of Rheumatology, 2017, 28, 174-182.	0.8	13
44	Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study. BMC Musculoskeletal Disorders, 2016, 17, 213.	1.9	12
45	Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 2835.	4.8	12
46	B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatology International, 2019, 39, 1889-1898.	3.0	12
47	DKK-1 Is Underexpressed in Mesenchymal Stem Cells from Patients with Ankylosing Spondylitis and Further Downregulated by IL-17. International Journal of Molecular Sciences, 2022, 23, 6660.	4.1	11
48	The impact of osteoporosis and vertebral compression fractures on mortality and association with pulmonary function in COPD: A meta-analysis. Joint Bone Spine, 2022, 89, 105249.	1.6	9
49	Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis. Rheumatology International, 2021, 41, 1203-1208.	3.0	8
50	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases. Mediterranean Journal of Rheumatology, 2021, 32, 218.	0.8	8
51	Adrenocorticotropic hormone: an effective â€œnaturalâ€•biologic therapy for acute gout?. Rheumatology International, 2020, 40, 1941-1947.	3.0	7
52	Periaortitis, hairy kidneys and bone lesions. Rheumatology, 2016, 55, 2118-2118.	1.9	6
53	Painless, eosinophilic infiltration of temporal arteries. Rheumatology, 2019, 58, 2065-2067.	1.9	6
54	Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis. Immunologic Research, 2020, 68, 39-47.	2.9	6

#	Article	IF	Citations
55	Cardiovascular Disease in the Systemic Vasculitides. Current Vascular Pharmacology, 2020, 18, 463-472.	1.7	6
56	A study of antigen-specific anti-cytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies. Rheumatology International, 2020, 40, 1689-1699.	3.0	5
57	DISH vs Spondyloarthritides. Mediterranean Journal of Rheumatology, 2019, 31, 81.	0.8	5
58	Anti-PD-1 associated retroperitoneal fibrosis. Rheumatology, 2021, 60, e329-e330.	1.9	4
59	Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo. Rheumatology International, 2011, 31, 841-842.	3.0	3
60	Serotonin and Systemic sclerosis. An emerging player in pathogenesis. Joint Bone Spine, 2021, 89, 105309.	1.6	3
61	Dickkopf-1 is downregulated early and universally in the skin of patients with systemic sclerosis despite normal circulating levels. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 45-49.	0.8	3
62	Calcified lymph nodes and systemic sclerosis. Mediterranean Journal of Rheumatology, 2018, 29, 97-98.	0.8	2
63	ACTH vs betamethasone for the treatment of acute gout in hospitalized patients: A randomized, open label, comparative study. Mediterranean Journal of Rheumatology, 2018, 29, 178-181.	0.8	2
64	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. Mediterranean Journal of Rheumatology, 2020, 31, 239.	0.8	2
65	Adrenocorticotropic hormone: A powerful but underappreciated therapeutic tool for acute crystal induced arthritis?. World Journal of Rheumatology, 2013, 3, 6.	0.5	2
66	ACTH vs steroids for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study. Rheumatology International, 2022, 42, 949-958.	3.0	2
67	Gout and foot drop. Joint Bone Spine, 2016, 83, 229.	1.6	1
68	First report of Mycobacterium celatumâ€“induced arthritis. Rheumatology, 2020, 59, 1772-1773.	1.9	1
69	Rice bodies in MRI. Joint Bone Spine, 2021, 88, 105079.	1.6	1
70	A Case Report of Favourable Response of Polymyositis to Methotrexate Monotherapy. Mediterranean Journal of Rheumatology, 2021, 31, 86.	0.8	1
71	Is there a link between IL-23/IL-17 and developmental pathways such as the Wnt and Hedgehog pathway?. Mediterranean Journal of Rheumatology, 2017, 28, 59-61.	0.8	1
72	Vision loss in giant cell arteritis: case-based review. Rheumatology International, 0, , .	3.0	1

#	Article	IF	Citations
73	AB0678â€…ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
74	Neck pain, red eyes and hearing loss. Rheumatology, 2020, 59, 4002-4002.	1.9	0
75	Grains de riz Ã lâ€™IRM. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 244.	0.0	0
76	Foreign Body Dactylitis. Mediterranean Journal of Rheumatology, 2021, 32, 158.	0.8	0
77	B cell depletion in scleroderma lung disease: A promising new treatment?. World Journal of Rheumatology, 2013, 3, 9.	0.5	0
78	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. Israel Medical Association Journal, 2019, 21, 292-297.	0.1	0
79	TIPIC syndrome. Joint Bone Spine, 2022, 89, 105396.	1.6	0